AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 142 min read$AXSM

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

Axsome Therapeutics (NASDAQ: AXSM) said it will release its second-quarter 2026 financial results on Aug. 10, 2026, before U.S. market open. Management will host a conference call at 8:00 a.m. ET and provide a business update. The company also noted a webcast and a 30-day replay on its website.

Original reporting
manilatimes.net
Published Jul 14, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 — source image
Source · manilatimes.net
Decision brief

The 30-second read

$AXSMNeutralMed
01

Why it matters

The main tradable element is the fixed earnings timeline, which can affect options pricing and pre-earnings positioning. No new results or guidance are disclosed in the text.

02

Market read

Provides a specific pre-market earnings release and call time for AXSM, enabling event-driven positioning.

03

What to watch

Traders should focus on what management plans to emphasize on the call (commercial performance of SUNOSI, AUVELITY, SYMBRAVO and any updates on solriamfetol/AXS-05), but those details are not provided here.

Relevance 4/10Novelty 5/10Timing: Ahead of Aug 10 pre-market Q2 2026 earnings release and 8:00 a.m. ET conference call.

Background

Axsome is a biopharmaceutical company with FDA-approved CNS products and multiple development programs; this PR is an earnings scheduling notice.

Company-level read

Ticker impact

$AXSMNeutralMedium confidence
Context

Axsome announced it will report Q2 2026 financial results on Aug 10 before the U.S. market open, with a call at 8:00 a.m. ET.

Expected impact

Likely modest near-term volatility around Aug 10 as traders position for results and guidance updates.

Evidence & confidence

The article contains a specific, time-bound catalyst (earnings release and call timing) but no new financial numbers, guidance, or trial/regulatory outcomes.

Market effects

Sector

Limited. Earnings timing for one CNS biopharma typically affects only near-term sentiment/volatility for the name.

Regional

Primarily U.S. pre-market and early-session trading around the earnings release.

Global

Low. No cross-border regulatory or deal implications are mentioned.

Counterpoint

What could challenge this read

Because the release date is already a known type of catalyst, the stock may trade more on expectations than on the announcement itself.

Key entities

  • company
    Axsome Therapeutics, Inc.

    NASDAQ-listed biopharmaceutical company scheduling Q2 2026 financial results for Aug 10, 2026 before market open.

Read at source← All news

Related articles

JUL 1
$AXSMMed

Why Axsome Stock Has Doubled In Nine Months

Forbes’ InnovationRx says Axsome Therapeutics’ stock doubled in nine months, lifting market cap from $6.1B to $12.6B, after FDA approval of Auvelity for Alzheimer’s agitation. Axsome reported $709M revenue for the latest 12 months (+64%) and forecasts peak Auvelity sales of $8B. It also acquired epilepsy and schizophrenia/Tourette candidates. Separately, HistoSonics’ Edison histotripsy tech and a Medicaid work-rule lawsuit are discussed.

forbes.com7 min
AUG 8
$CATMedAI 8/10

Critical Minerals: How Data Centres are Boosting Caterpillar

Caterpillar shares rose about 12% on 4 August after its Q2 results beat analyst expectations. The company reported revenue of $20.54bn, up 24% year on year, and adjusted EPS of $8.17 versus $6.20 expected. Operating profit was $4.3bn. Order backlog reached $72.1bn, up 92%, supporting construction and power demand tied to data centres.

miningdigital.com6 min
AUG 8
$LEEMed

Lee Enterprises, Incorporated Q3 2026 Earnings Call Summary

Lee Enterprises reported Q3 2026 progress toward a digital-first model, saying digital revenue was 57% of total revenue. It cited a 15% cash cost reduction and fifth straight quarter of comparable adjusted EBITDA growth, raising full-year adjusted EBITDA guidance to 22% to 28%. The company expects about $18M annual interest savings, positive net income of $5.2M, and plans debt paydown using excess cash and non-core asset sales.

yahoo.com6 min
AUG 8
$LNGMed

Cheniere Energy, Inc. Q2 2026 Earnings Call Summary

Cheniere Energy’s Q2 2026 call cited production outperformance and faster Corpus Christi Stage 3 startup for a second guidance raise. Full-year 2026 adjusted EBITDA guidance was revised to $7.9B-$8.4B. Management expects Sabine Pass Phase 1 FID by early 2027, targets dividend growth of at least 10% annually, and issued $1.75B dual-tranche bonds extending maturities to 2056.

yahoo.com6 min